Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind crossover fMRI study of GW876008 and GSK561679 in social anxiety disorder
2006-004212-48Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emicerfont and verucerfont in Social Anxiety Disorder (SAD) (4 arms), sponsored by GSK. Primary endpoint: Amygdala BOLD fMRI response during emotional face matching task. Started Jun 2012; status: completed.
02
Drugs
emicerfontverucerfont
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on 2006-004212-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004212-48.